Birgitta Versluijs

127 Respiratory virus infection pre-HCT and alloimmune-mediated lung syndromes TABLE S1. Predictor analyses for outcome of interest allo-LSs (BOS plus IPS) Univariate analyses (N = 24) HR (95% CI) P value Age at HCT 1.0 (0.9-1.0) .28 Sex  Male  Female 1 1.5 (1.0-2.3) .04 * HCT indication  Malignancy  Bone marrow failure syndrome  Inborn error of metabolism  Primary immune deficiency 1 0.0 (0-0) 2.8 (1.1-7.6) 2.5 (0.9-6.6) .98 .04 * .07 * Conditioning  Chemotherapy-based  TBI-based 1 0.04 (0.0-4.0) .17 Donor  MSD  MUD  uCB 1 1 (0.3-3.1) 0.8 (0.3-2.2) .99 .73 HLA matching  MSD 10/10 MUD  9/10 MUD  6/6 uCB  4-5/6 uCB 1 3.4 (0.7-15.9) 0.9 (0.3-2.6) 1.4 (0.5-3.5) .11 .82 .52 CMV serology recipient  Negative  Positive 1 1.7 (0.6-4.3) .30 NPA  RV negative  RV positive 1 0.4 (0.0-3.9) .45 BAL  RV negative  RV positive 1 5.5 (2.0-14.7) .001 * Abbreviations: CMV, Cytomegalovirus; MSD, matched sibling donor; MUD, matched unre- lated donor; TBI, total-body irradiation; uCB, unrelated cord blood. * Statistically significant 7